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Background: Deficiency of complex II (succinate dehydrogenase, SDH) represents a rare cause of mitochondrial
disease and is associated with a wide range of clinical symptoms. Recently, mutations of SDHAF1, the gene
encoding for the SDH assembly factor 1, were reported in SDH-defective infantile leukoencephalopathy. Our goal
was to identify SDHAF1 mutations in further patients and to delineate the clinical phenotype.
Methods: In a retrospective data collection study we identified nine children with biochemically proven complex II
deficiency among our cohorts of patients with mitochondrial disorders. The cohort comprised five patients from
three families affected by SDH-defective infantile leukoencephalopathy with accumulation of succinate in
disordered cerebral white matter, as detected by in vivo proton MR spectroscopy. One of these patients had
neuropathological features of Leigh syndrome. Four further unrelated patients of the cohort showed diverse clinical
phenotypes without leukoencephalopathy. SDHAF1 was sequenced in all nine patients.
Results: Homozygous mutations of SDHAF1 were detected in all five patients affected by leukoencephalopathy
with accumulated succinate, but not in any of the four patients with other, diverse clinical phenotypes. Two sisters
had a mutation reported previously, in three patients two novel mutations were found.
Conclusion: Leukoencephalopathy with accumulated succinate is a key symptom of defective complex II assembly
due to SDHAF1 mutations.
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Assembly factorBackground
Deficiency of complex II (succinate dehydrogenase,
SDH) is a rare cause of disordered oxidative phosphor-
ylation (OXPHOS) and is associated with a wide range
of clinical symptoms. Among our cohorts of more
than 1200 patients with defects in OXPHOS we found
only nine with biochemically proven deficiency of
complex II.
In 2001 we reported a characteristic finding in loca-
lized in vivo cerebral proton magnetic resonance* Correspondence: aohlenb@gwdg.de; kbrock@med.uni-goettingen.de
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distribution, and reproduction in any mediumspectroscopy (MRS) in three patients from two unre-
lated families, two German sisters of Turkish origin
(family A) and one Norwegian boy (family B), presenting
with symptoms and MRI signs of leukoencephalopathy
[1]. MRS revealed a prominent singlet at 2.40 ppm in
cerebral and cerebellar white matter originating from
accumulated succinate in affected white matter. Bio-
chemical investigations demonstrated isolated deficiency
of complex II in muscle and fibroblasts of these patients.
Recently, homozygous mutations in SDHAF1, encod-
ing a new LYR-motif protein, were detected in 2 families
from Turkey and Italy with several children affected by
infantile leukoencephalopathy with defective SDH [2,3].
We investigated whether SDHAF1 is mutated in our
nine patients with complex II deficiency with eitherntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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clinical phenotypes without leukoencephalopathy.
Patients and methods
The Table 1 summarizes the clinical, neuroradiological,
and biochemical features of five patients from three fam-
ilies with SDH-defective leukoencephalopathy and 4 un-
related patients with other clinical phenotypes of
complex II deficiency. Details of clinical and neuroradio-
logical features of patients #1, #2 and #3 were described
previously [1].
In family A, patients #1 and #2 were the second and
fifth children of healthy, consanguineous (first cousins)
German parents of Turkish origin belonging to a big
pedigree where SDHAF1 mutations were previously
described [2]. Both sisters presented with motor deteri-
oration and spasticity in the 2nd half of their first year of
life. MRI of the brain revealed extensive T2-
hyperintensities in cerebral and cerebellar white matter,Table 1 Clinical, neuroradiological, biochemical and genetic f
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succinate. The elder sister died from multiorgan failure
with severe lactic acidosis at age 18 months. Postmortem
examination revealed histopathological features and
topic patterns of a multifocal spongiform encephalomye-
lopathy consistent with Leigh syndrome [1]. The
younger sister showed severe motor disability with
marked spastic tetraparesis and relatively preserved cog-
nitive abilities. She died at age 11 years.
In family B, patient #3 was the first of three children
of allegedly unrelated Norwegian parents coming from
neighboring areas. With onset at 20 months increasing
spasticity and clumsiness were observed. Cerebral MRI
and proton MRS indicated a leukoencephalopathy with
accumulation of succinate. Biochemical analysis of fibro-
blasts demonstrated an isolated deficiency of complex II.
At present, at age 16 years, his main clinical feature is
spastic paraplegia. He has suffered single epileptic sei-
zures but has no preventive treatment. The cognitiveeatures of five patients from three families with
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motor skills and language function are good, and he is
attending ordinary school with some facilitation. A
follow-up cranial MRI performed at age 9 years showed
leukoencephalopathy with supratentorial bilateral T2-
hyperintensities (Figure 1), largely unchanged compared
with neuroimaging performed 5 years before [1].
In family C, patients #4 and #5 were the first and sec-
ond of three daughters of consanguineous Palestinian
parents. With onset at 14 and 4 months, respectively,
they showed motor regression and spasticity. In patient
#4, best motor function was standing up, best mental
function was speaking a few words. In patient #5, best
motor function was head control at 5 months, best so-
cial function was smiling at 3 months. In both girls MRI
and proton MRS of the brain revealed bilateral leukoen-
cephalopathy and accumulation of succinate. Complex II
deficiency was demonstrated in muscle or lymphocytes
or both. Patient #4 died at age 5 years from pneumonia.
Postmortem was not performed.
Additional four patients (#6 to #9) presented with
other, diverse clinical features. Patient #6 showedFigure 1 (A-C) Axial T2-weighted and (D) coronal FLAIR-weighted MR
T2-hyperintensities in cerebral periventricular white matter. Involveme
are visible. Peripheral U-fibers are spared. Lesions are largely unchanged coexercise intolerance and SDH-defective myopathy. He
had normal cognitive abilities with very good perform-
ance at school as well as normal MRI and MRS of the
brain. After initial normal development, patient #7 suf-
fered from acute liver failure requiring liver transplant-
ation with fatal outcome at age 2 years. Psychomotor
retardation with muscle weakness and hearing impair-
ment were main clinical features of patient #8. Patient
#9 showed psychomotor retardation as well as muscular
hypotonia and weakness. In all of these four patients,
complex II deficiency was demonstrated biochemically
in muscle or liver. MRI of the brain was performed in
patients #6, #8, and #9 (with additional proton MRS of
the brain in #6) and did not reveal leukoencephalopathy
or any other abnormalities.
Genetic analysis
Total genomic DNA was extracted from peripheral
blood leukocytes by standard techniques. Primers for
DNA amplification and sequencing were designed to
cover exon 1 of SDHAF1 along with flanking segments
(GenBank Reference No. NC_000019.9). Screening forimages of patient 3 at 9 years of age show widespread bilateral
nt of the pons (C, full white arrow) and cystic lesions (D, open arrow)
mpared to neuroimaging at age 4 years1.
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Terminator Ready Reaction chemistry on an ABI PRISM
3100 Avant genetic analyzer (Applied Biosystems, Darm-
stadt, Germany). All identified mutations were con-
firmed by direct sequencing of two different PCR
amplification products on forward and reverse strands.
Primer sequences as well as PCR and sequencing condi-
tions are available on request. Informed consent was
obtained for each patient from the parents. The Institu-
tional Review Board approved the study.
Results
Patients #1 and #2, siblings of Turkish origin, were
homozygous for a missense mutation c.164 G > C, cor-
responding to p.Arg55Pro, with both unaffected parents
being heterozygous for the mutation.
We found a homozygous c.22C > T nonsense muta-
tion in patient #3 of Norwegian origin predicted to re-
sult in a premature stop of translation (p.Gln8X). Two
healthy siblings as well as the unaffected parents were
heterozygous carrier for this variant.
In patients #4 and #5, siblings from consanguineous
parents of Palestinian origin, a missense mutation c.170
G > A, corresponding to p.Gly57Glu was detected. This
mutation affects the same highly conserved residue,
Gly57, as the mutation Gly57Arg reported previously in
an Italian family [2]. This observation indicates a funda-
mental role for Gly57 for the function of SDHAF1.
Molecular analysis of the coding sequence as well as
of adjacent promoter and 30UT regions revealed no se-
quence alterations in patients #6 to #9.
Discussion
Mutation analysis of the SDHAF1 gene revealed muta-
tions in five patients with SDH-defective infantile leu-
koencephalopathy. The missense mutation detected in
patients #1 and #2 was reported previously in a large
multiconsanguineous kindred of Turkish origin with
several affected children [2,3]. Family history of the
siblings described here (patients #1 and #2) indicates
common ancestry with those patients. The homozy-
gous nonsense mutation demonstrated in patient #3
and the homozygous missense mutation detected in
patients #4 and #5 were not reported before.
Succinate dehydrogenase participates in the electron
transfer in the respiratory chain and in succinate catabol-
ism in the Krebs cycle and consists of four subunits, all
encoded by the nuclear genome [4]. Isolated complex II
deficiency is a relatively rare cause of mitochondrial dis-
ease compared to other respiratory chain defects, but is
associated with a wide range of clinical features [5].
Mutations in the four genes, SDH-A, -B, -C, -D, have
been reported, with remarkably diverse phenotypes.
Mutations in the SDHA gene were found to be associatedwith Leigh syndrome [6], late onset neurodegenerative
disease [7] and dilated cardiomyopathy [8]. Heterozygous
germline mutations in SDHA, SDHB, SDHC, and SDHD
cause hereditary paragangliomas and pheochromocyto-
mas [9], and germline mutations in SDHB and SDHC
were found to be associated with gastrointestinal stromal
tumors [4]. Recently, a mitochondrial encephalopathy
was reported to be caused by SDHD mutations [10].
Whereas an increasing number of assembly factors
have been identified for complex I, III, and cytochrome
oxidase, little was known concerning the assembly of
complex II. Recently two genes involved in this process
were detected in humans, and the first, termed SDHAF1,
was found by linkage analysis in two families with SDH-
defective infantile leukoencephalopathy [2]. Yeast experi-
mentation indicated that the protein encoded by this
gene is required for the stable assembly and full function
of the SDH complex. The protein was thus termed SDH
assembly factor 1 (SDHAF1) [2].
In the same year, mutations in the SDHAF2 (SDH5)
gene encoding a protein necessary for the flavination of
the subunit SDHA were detected in patients with para-
ganglioma [10]. The cause of such diverse phenotypes
associated with defective assembly factors of complex II
remains enigmatic to date.
Our results confirm the pathogenicity of SDHAF1
mutations in infantile leukoencephalopathy due to de-
fective succinate dehydrogenase. Our patients with
complex II deficiency not associated with leukoence-
phalopathy but with other, diverse clinical phenotypes
including myopathy with exercise intolerance, acute
liver failure, psychomotor delay, muscle weakness, and
hearing impairment did not carry a SDHAF1 mutation.
Further studies will clarify whether infantile leukoence-
phalopathy with accumulation of succinate, readily de-
tectable by in vivo proton MR spectroscopy of the
brain, is pathognomonic for SDHAF1 deficiency.
To date, clinical features comprising motor regression
with spasticity and neuroradiological features including
bilateral leukoencephalopathy with elevated succinate on
cerebral proton MRS are the suggestive findings pointing
to a SDHAF1 mutation.
Treatment with riboflavin was found to be effective in
selected mitochondrial disorders, including SDH defi-
ciency [3]. In our cohort, riboflavin treatment was ap-
plied in patients #2, #4, and #5 (SDHAF1 mutations) as
well as #6 (SDH-defective myopathy with exercise in-
tolerance). Riboflavin treatment resulted in no discern-
able effect in the 3 patients with SDHAF1 mutations.
Patient #6 had clear benefit from this treatment with
markedly prolonged motor endurance.
The clinical course in our five patients with SDHAF1
mutations is strikingly diverse. Patients #1, #2, and #4,
all carrying missense mutations, died at age 18 months,
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features of Leigh syndrome in one of them. In contrast,
patient #3, who carries a stop mutation, follows a milder
course with spastic paraparesis as the main clinical fea-
ture 14 years after onset and stable white matter changes
on MRI over many years. We hypothesize that an atyp-
ical starting codon could be present resulting in synthe-
sis of a partially functional protein. Further studies are
needed to elucidate the pathomechanism of this stop
mutation. This variation points to influential further
genetic or epigenetic factors shaping the phenotype of
defective complex II assembly due to mutated SDHAF1.
Abbreviations
SDH: Succinate dehydrogenase; SDHAF1: SDH assembly factor 1;
OXPHOS: Oxidative phosphorylation; MRI: Magnetic resonance imaging;
MRS: Magnetic resonance spectroscopy; 30UT region: 30 untranslated region;
LYR-motif: Pattern in protein structure consisting of leucine, tyrosine, and
arginine.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AO carried out the molecular genetic studies. SE, AB, JS contributed with
clinical data. AS carried out the biochemical investigations. OE contributed
with clinical and genetic information and interpretation of data. JG
participated in the design of the study and interpretation of data. KB
conceived of the study, provided clinical information and drafted the
manuscript. All authors participated in finalizing the manuscript and read
and approved the final manuscript.
Acknowledgements
We wish to thank all patients and their families for their generous help.
Supported by the Deutsche Forschungsgemeinschaft (GA354/9-1) and the
Bundesministerium für Bildung und Forschung (BMBF) through the German
Leukodystrophy Network.
Author details
1Department of Pediatrics and Pediatric Neurology, Georg August University,
Robert Koch Str. 40, Göttingen 37075, Germany. 2Pediatric Neurology Unit,
Hadassah, Hebrew University Medical Center, Jerusalem, Israel. 3Department
of Pediatric Medicine, Child Habilitation Unit, Ålesund Hospital, Ålesund,
Norway. 4Department of Pediatrics, Drammen Sykehus, Drammen, Norway.
5The Department of Genetic and Metabolic Diseases, Hadassah, Hebrew
University Medical Center, Jerusalem, Israel.
Received: 18 April 2012 Accepted: 19 September 2012
Published: 20 September 2012
References
1. Brockmann K, Bjornstad A, Dechent P, Korenke CG, Smeitink J, Trijbels JM,
Athanassopoulos S, Villagran R, Skjeldal OH, Wilichowski E, Frahm J,
Hanefeld F: Succinate in dystrophic white matter: a proton magnetic
resonance spectroscopy finding characteristic for complex II deficiency.
Ann Neurol 2002, 52:38–46.
2. Ghezzi D, Goffrini P, Uziel G, Horvath R, Klopstock T, Lochmüller H, D’Adamo
P, Gasparini P, Strom TM, Prokisch H, Invernizzi F, Ferrero I, Zeviani M:
SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated
in SDH-defective infantile leukoencephalopathy. Nat Genet 2009,
41:654–656.
3. Bugiani M, Lamantea E, Invernizzi F, Moroni I, Bizzi A, Zeviani M, Uziel G:
Effects of riboflavin in children with complex II deficiency. Brain Dev
2006, 28:576–581.
4. Rutter J, Winge DR, Schiffman JD: Succinate dehydrogenase - Assembly,
regulation and role in human disease. Mitochondrion 2010, 10:393–401.
5. Rustin P, Rötig A: Inborn errors of complex II–unusual human
mitochondrial diseases. Biochim Biophys Acta 2002, 1553:117–122.6. Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-
Péquignot E, Munnich A, Rötig A: Mutation of a nuclear succinate
dehydrogenase gene results in mitochondrial respiratory chain
deficiency. Nat Genet 1995, 11:144–149.
7. Taylor RW, Birch-Machin MA, Schaefer J, Taylor L, Shakir R, Ackrell BA,
Cochran B, Bindoff LA, Jackson MJ, Griffiths P, Turnbull DM: Deficiency of
complex II of the mitochondrial respiratory chain in late-onset optic
atrophy and ataxia. Ann Neurol 1996, 39:224–232.
8. Levitas A, Muhammad E, Harel G, Saada A, Caspi VC, Manor E, Beck JC,
Sheffield V, Parvari R: Familial neonatal isolated cardiomyopathy caused
by a mutation in the flavoprotein subunit of succinate dehydrogenase.
Eur J Hum Genet 2010, 18:1160–1165.
9. Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, Jouanno E,
Jeunemaitre X, Bénit P, Tzagoloff A, Rustin P, Bertherat J, Favier J, Gimenez-
Roqueplo AP: SDHA is a tumor suppressor gene causing paraganglioma.
Hum Mol Genet 2010, 19:3011–3020.
10. Hahn D, Schaller A, Jackson CB, Häberli A, Gallati S, Vella S, Nuoffer JM: First
report of a mitochondrial encephalopathy associated to SDHD
mutations. J Inherit Metab Dis 2010, 33(Suppl 1):S75.
doi:10.1186/1750-1172-7-69
Cite this article as: Ohlenbusch et al.: Leukoencephalopathy with
accumulated succinate is indicative of SDHAF1 related complex II
deficiency. Orphanet Journal of Rare Diseases 2012 7:69.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
